Low-value health care costs $345B each year and provides little benefit
By Katie Koziara | February 26, 2020
Low-value health care is treatment that offers little to no clinical benefit to patients yet is a major drain of resources often at the detriment to patients. Low-value health care is one of the...
Read More
Rare Disease Day 2020: Progress toward cures
By Richard Moscicki, M.D. | February 24, 2020
Today kicks off Rare Disease Week, an annual opportunity to celebrate the incredible progress that has been made to treat rare diseases and reflect on the need for continued research and...
Read More
Addressing barriers that inhibit value-based contracts
By Katie Koziara | February 21, 2020
With 56 new medicines approved by the U.S. Food and Drug Administration (FDA) in 2019 and over 8,000 medicines in development around the globe, innovative medicines are transforming the way we...
Read More
Helping those affected by the coronavirus
By Stephen J. Ubl | February 20, 2020
Updated as of 4/1/2020 America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, a disease caused by a novel strain of coronavirus...
Read More
Fact Check: HCCI analysis overstates medicine spending and prices
By Katie Koziara | February 19, 2020
A recent analysis from the Health Care Cost Institute (HCCI) on health care spending overestimates medicine spending and pricing and mischaracterizes the true drivers of health care spending in...
Read More
IP Explained: Four key takeaways from new Bayh-Dole white paper
By Tom Wilbur | February 19, 2020
2020 marks the 40th anniversary of the Bayh-Dole Act being signed into law. The Bayh-Dole Act laid the foundation for effective technology transfer that modernized the U.S. economy, set a global...
Read More
R&D Focus: New report shows nearly 600 medicines in development for pediatric patients
By Andrew Powaleny | February 13, 2020
America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and...
Read More
Across the country, the biopharmaceutical sector supports millions of jobs in its pursuit to discover ground-breaking treatments and cures for patients around the world.
Read More
Trump administration must defend and protect U.S. innovation
By Priscilla VanderVeer | February 6, 2020
PhRMA recently submitted comments to the Office of the United States Trade Representative (USTR)’s Special 301 Report, calling on the Trump administration to defend American biopharmaceutical...
Read More
Working together to combat coronavirus
By Richard Moscicki, M.D. | February 6, 2020
The World Health Organization (WHO) recently declared the outbreak of 2019-nCoV, a novel strain of coronavirus that originated in Wuhan, China, a global health emergency. In the last three weeks,...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
